Recruiting
Axial spondyloarthritis
RecruitingStudy on Axial Spondyloarthritis Treatment Using Technetium-Labeled Certolizumab Pegol for Patients with Axial Spondyloarthritis
InvestigationalNo placebo
Study on Axial Spondyloarthritis Treatment Using Technetium-Labeled Certolizumab Pegol for Patients with Axial Spondyloarthritis
InvestigationalNo placebo
- Disease:Axial spondyloarthritis
- Substances:Technetium (99MTC) certolizumab pegol
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Technetium (99MTC) certolizumab pegol
